Home > Companies > Recursion Pharmaceuticals

Recursion Pharmaceuticals

Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion’s rich, relatable database of more than a petabyte of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

13th Global Drug Delivery And Formulation Summit

Pharmaceutics And Novel Drug Delivery Systems

INTERNATIONAL CONFERENCE ON MEDICAL, BIOLOGICAL AND PHARMACEUTICAL SCIENCES

24th World Congress On Pharmaceutical Research and Drug Discovery

Drug Discovery And Communal Trial

ACCORD 2022 Interdisciplinary Conference on Drug Sciences

Related News

PHARMACY MARKET

IQVIA AND NRX PHARMACEUTICALS COLLABORATE ON POTENTIAL MEDICAL SUPPORT FOR NOVEL COVID-19 TREATMENT

IQVIA™ | September 14, 2021

IQVIA™ , a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmac...

PHARMACY MARKET

KEEP, THE MODERN MEDICINE CABINET, ANNOUNCES PARTNERSHIP WITH MCKESSON CANADA

KEEP Labs Inc. | January 28, 2022

KEEP Labs, the Modern Medicine Cabinet and KARE by KEEP Adherence Platform developers, are pleased to announce a partnership with McKesson Canada to provide a novel solution for Canadians taking specialty medications. A majority of healthcare activities occur in the home, making it a critical place to monitor, engage and support patients. KEEP's state of the art technology and intuitive design allows McKesson Canada to provide an award-winning adherence platform that supports ...

COVID-19 BRINGS DIVISIONS ON HYDROXYCHLOROQUINE, REOPENING

Fiercepharma | May 19, 2020

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. As the pandemic plays out, political divisions have unfolded around hydroxychloroquine and reopening economies, for starters. At center stage last week was a House hearing over ousted Biomedical Advanced Research and Development Authority (BARDA) Director Rick Bright’s whistleblower complaint. While...

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

PHARMACY MARKET